Appendix "B" to Report PED14091

Page 1 of 1

lumiracapital

Carolynn Reid, B.Comm., EcD **Business Development Consultant** Economic Development Division, Planning and Economic Development Department City of Hamilton 71 Main St. west, 7th floor Hamilton, ON L8P4Y5

April 3, 2014

Dear Carolyn,

As you are aware, Lumira Capital is one of the leading venture capital companies in Canada that makes investments all over North America, exclusively in the life sciences area. We believe that the current proposal to create a dynamic relationship between McMaster and the Fraunhofer Institute should be of great interest to a number of players in the Cell Therapy area where we were one of the first to invest. Our investee company, Argos Therapeutics (Durham, NC) has worked closely with McMaster's cancer cell therapy group in the past and recognized early in its development the need for automated manufacturing systems to produce cell therapy products at an affordable cost. Argos had to start from scratch and has now built a system that fits its needs for the time being. However, the field of immune cell therapy is growing rapidly so much so, that this year Science magazine described the area as the breakthrough of 2013. There are now a growing number of companies that are rushing to adopt the cell therapy approach to treat patients with cancer and chronic viral infections such as hepatitis C and HIV. Most have not yet dealt with the need to produce an automated manufacturing solution to enable these new therapeutics to be cost-effective. McMaster's decision to bring together its strength in cell therapy with that of the engineering school is exactly what is required to put Hamilton at the front of the field of solution providers for advanced manufacturing of cell therapy-based products. The Fraunhofer and McMaster have already made significant investment in this area and their proposed collaboration will expand McMaster's global reach and allow it to build additional relationships with European companies.

The field of cell therapy has just begun to get traction in the pharmaceutical world and automation is a key to efficient production. I believe that a natural outcome of this new proposed McMaster/Fraunhofer collaboration is the translation of the work into commercial products made in Hamilton. As the city of Hamilton moves to expand its manufacturing base into the new economy, an investment in this project will be critical.

Sincerely. Under about-BS

Brian J. Underdown, Ph.D.

Managing Director

20 Bay Street, 11th Floor, Suite 303 Toronto, ON, Canada M5J 2N8 t. 416.213.4223 f. 416.213.4232

montreal 1550 Metcalfe Street, Suite 502 Montreal, PQ, Canada H3A 1X6 t. 514.844.6927 f. 514.844.5607 cambridge 245 First Street, Suite 1800 Cambridge, MA, USA 02142

t. 617.444.8550 f. 253.484.4262

mountain view

800 West El Camino Real, Suite 180 Mountain View, CA, USA 94040 t. 650.943.2448. f. 650.943.2449

lumiracapital.com